Phathom Pharmaceuticals, Inc.
$11.5M 93,370 recipients
Compare payment profiles
CMS Open Payments · Program Year 2024
Iovance Biotherapeutics, Inc.
Iovance Biotherapeutics, Inc. reported $11,481,371.75 across General Payments, Research, and Ownership to 604 physicians and teaching hospitals across 1,476 transactions.
- $11.5M Top 10% payer
- All-tracks total
- 1,476 Top quartile volume
- Transactions
- 604 Above-median reach
- Recipients
- #152
- of 1,925 companies
Iovance Biotherapeutics, Inc. reported $11,481,371.75 across all CMS Open Payments tracks (General + Research + Ownership) to 604 physicians and teaching hospitals in Program Year 2024 - ranking #152 of 1,925 reporting manufacturers (0.1% of the all-tracks industry total); General Payments alone were $114,707.51, averaging $19.0K per recipient.
How Iovance Biotherapeutics, Inc.'s $11.5M all-tracks total breaks down
Iovance Biotherapeutics, Inc.'s payment reach score
Each tracked dimension is percentile-scored against the national companies corpus, then averaged across only the dimensions that apply to this company, a neutral scale measure of reporting activity, not a rating of quality, safety, or ethics.
Overall reach score
F
47/100
Total payments
A
100/100
Transaction volume
F
21/100
Physician reach
F
15/100
Payment type diversity
D
50/100
Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.
CMS Sunshine Act warrant
Manufacturer iovance-biotherapeutics-inc Iovance Biotherapeutics, Inc.
$11.5M · #152/1,925 · 0.1% industry · PY2024
- TOT $11.5M
- RANK #152
- SHARE 0.1%
- TXN 1,476
- RCP 604
- CAT 4
- GEN $114.7K
- TOP1 12.1%
- PY 2024
Volume peers
Nearest volume peer: Phathom Pharmaceuticals, Inc. ($11.5M)
Iovance Biotherapeutics, Inc. sits among 1,925 manufacturers disclosing under the Physician Payments Sunshine Act. Volume peers below are nearest by all-tracks total, not corporate affiliates. Open the company rankings →
What the Data Shows for Iovance Biotherapeutics, Inc.
The all-tracks total above combines three CMS reporting categories - General Payments, Research Payments, and Ownership/Investment interests - not one undifferentiated figure. For Iovance Biotherapeutics, Inc., that total blends General Payments (day-to-day consulting, meals, travel and speaking fees, shown separately above) with Research and Ownership/Investment interest records, each governed by its own CMS reporting rules. CMS publishes each Program Year's data roughly 12 months after the reporting period ends, so this reflects the most recently released cycle; see our methodology for how the tracks are standardized and compared across companies.
12 transactions worth $40.0K make "Honoraria" the top general-payment category in the 4-category breakdown below, 34.9% of General Payments (see our methodology for how research and ownership payments are reported separately).
General Payment Breakdown by Type
Across 4 types of general payments, Iovance Biotherapeutics, Inc.'s largest category was "Honoraria" at $40.0K - 34.9% of General Payments.
Iovance Biotherapeutics, Inc. reports 4 general-payment categories - the top three are Honoraria (34.9%), Consulting Fee (29.5%), and Food and Beverage (23.3%). The remaining 1 category make up 12.3% of this company's reported general-payment total. That multi-category mix is the kind of profile single-category reporters cannot show.
How Iovance Biotherapeutics, Inc. divides its payments
General-payment categories, ordered by reported total
| Payment Type | Amount | Transactions | % of Total |
|---|---|---|---|
| Honoraria | $40.0K | 12 | 34.9% |
| Consulting Fee | $33.8K | 16 | 29.5% |
| Food and Beverage | $26.7K | 524 | 23.3% |
| Travel and Lodging | $14.1K | 52 | 12.3% |
Recipient Concentration in General Payments
The five largest recipient relationships account for $45,173.56 (39.4%) of $114,707.51 in this company's General Payments records across 411 recipients.
General Payments scope note
Program Year 2024 General Payments view only: excludes research and ownership/investment records, so it is not the all-category company total above.
Largest General-Payment relationships for Iovance Biotherapeutics, Inc.
The five named recipients with the highest reported General Payments from this company
- 1
Joel Neal
$13,875.00 across 9 reported transactions
- 2
Amanda Kirane
$10,812.26 across 18 reported transactions
- 3
David Carbone
$7,767.21 across 10 reported transactions
- 4
Benjamin Creelan
$7,749.19 across 10 reported transactions
- 5
Thach-Giao Truong
$4,969.90 across 9 reported transactions
Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.
Spend vs. Concentration
Iovance Biotherapeutics, Inc. ranks #152 of 1,925 by total payments (top 8% by spend) but spreads that money notably more broadly than its spend rank alone would suggest -- #1,295 of 1,838 by HHI (bottom 30% least concentrated), a wider distribution than most similarly sized payers.
View all 12 companies in this HHI neighborhood as a list
- Minerva Surgical, Inc : $53.9K total payments, HHI 503
- Sterilmed, Inc. : $263.8K total payments, HHI 500
- Merge Healthcare Incorporated : $6.9K total payments, HHI 499
- Alnylam Pharmaceuticals Inc. : $6.5M total payments, HHI 498
- Nxstage Medical, Inc. : $106.2K total payments, HHI 496
- Adaptive Biotechnologies Corporation : $462.3K total payments, HHI 495
- Iovance Biotherapeutics, Inc. (this company) : $114.7K total payments, HHI 489
- Arjo Inc. : $151.8K total payments, HHI 489
- Banner Life Sciences, LLC : $82.4K total payments, HHI 487
- FUJIFILM Sonosite, Inc. : $257.0K total payments, HHI 486
- restor3d, inc. : $1.6M total payments, HHI 486
- Micro-tech Endoscopy USA, Inc. : $159.3K total payments, HHI 483
Similarly Concentrated Companies
Companies whose General Payments are spread across recipients about as (un)evenly as Iovance Biotherapeutics, Inc.'s, measured by the same HHI concentration index above, not by payment size.
What HHI 2,500 means here
2,500 is the DOJ/FTC merger-guidelines threshold for "highly concentrated" markets; used here only as a familiar concentration reference, not a legal finding about Iovance Biotherapeutics, Inc..
Companies with Similar Payment Volumes
Open a profile or compare a similar company's CMS-reported payment pattern with Iovance Biotherapeutics, Inc..
Showing 6 of 1,924 companies with CMS-reported payment data.
Ocular Therapeutix, Inc.
$11.4M 4,194 recipients
Compare payment profiles
IBSA Institut Biochimique SA
$11.4M 17 recipients
Compare payment profiles
Tris Pharma Inc
$11.4M 23,649 recipients
Compare payment profiles
Orthofix Medical, Inc.
$11.6M 12,682 recipients
Compare payment profiles
Genmab A/S
$11.6M 1 recipients
Compare payment profiles
Put this to use
Iovance Biotherapeutics, Inc. ranks #152 of 1,925 by all-tracks total payments, led by "Honoraria".
- See where Iovance Biotherapeutics, Inc. sits among every top spender on the full leaderboard. Top 100 by total payments
- Compare "Honoraria" spend across every manufacturer, not just Iovance Biotherapeutics, Inc.. Payment type breakdowns
- New to Open Payments? Learn what these figures do and do not show. Read the guide
Reported payments reflect what companies disclosed to CMS; a payment is not evidence of wrongdoing.
Data sourced from CMS Open Payments (Physician Payments Sunshine Act). See our methodology for details. Retrieved and formatted by PlainPharmaWatch
Disclaimer
This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.
Read our methodology - how this data is sourced, computed, and verified.
Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-26.